Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2011-04-05
2011-04-05
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reissue Patent
active
RE042274
ABSTRACT:
Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
REFERENCES:
patent: 2004 196769 (2004-07-01), None
patent: WO 2007/096662 (2007-08-01), None
Tamamura et al. (“Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides,” Current HIV Research, 2005, 3, 289-301).
Grande, et al., “Small Molecules Anti-HIV Therapeutics Targeting CXCR4,”Curr. Pharm. Design14:385-404 (2008).
Tamamura et al., “Development of Low Molecular Weight CXCR4 Antagonists by Exploratory Structural Tuning of Cyclic Tetra- and Pentapeptide-Scaffolds Towards the Treatment of HIV Infection, Cancer Metastasis and Rheumatoid Arthritis,”Curr. Med. Chem.14:93-102 (2007).
Tamamura, et al., “Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides,”Curr. HIV Research3:289-301 (2005).
Ueda, et al., “Structure-Activity Relationships of Cyclic Peptide-Based Chemokine Receptor CXCR4 Antagonists: Disclosing the Importance of Side-Chain and Backbone Functionalities,”J. Med. Chem.50:192-198 (2007).
Kohn Wayne David
Peng Sheng-Bin
Yan Liang Zeng
Bradley Christina
Castetter Andrea M.
Eli Lilly and Company
LandOfFree
Cyclic peptide CXCR4 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic peptide CXCR4 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptide CXCR4 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678625